Roth Capital Reiterates “Buy” Rating for Mast Therapeutics Inc (MSTX)

roth-capital-reiterates-8220buy8221-rating-for-mast-therapeutics-inc-mstx.jpg

Mast Therapeutics Inc (NASDAQ:MSTX)‘s stock had its “buy” rating reaffirmed by research analysts at Roth Capital in a report released on Monday. They currently have a $2.00 price target on the stock. Roth Capital’s price target suggests a potential upside of 226.26% from the company’s previous close.
A number of other research analysts have also recently commented on the stock. Maxim Group reissued a “buy” rating and issued a $5.00 target price on shares of Mast Therapeutics in a report on Thursday, June 9th. Zacks Investment Research cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $3.00 target price on shares of Mast Therapeutics in a report on Thursday, July 28th.
Mast Therapeutics (NASDAQ:MSTX) traded down 2.698% on Monday, reaching $0.613. 6,291,435 shares of the company traded hands. The stock’s market capitalization is $129.84 million. Mast Therapeutics has a one year low of $0.21 and a one year high of $0.71. The firm has a 50 day moving average of $0.42 and a 200-day moving average of $0.36.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/11/roth-capital-reiterates-buy-rating-for-mast-therapeutics-inc-mstx.html

Mast Therapeutics (NASDAQ:MSTX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. On average, analysts anticipate that Mast Therapeutics will post ($0.21) EPS for the current year.

Receive News & Ratings for Mast Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mast Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Roth Capital Reiterates “Buy” Rating for Mast Therapeutics Inc (MSTX)"

Leave a comment

Your email address will not be published.

*